GlassScriptPhysician profile
Brian Kenneth Brown
NPI 1952801169
$5,800.58
in general payments reported to CMS, 2019-2025
38 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,090 · 2023: $1,165 · 2024: $1,366 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,292.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $774.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $521.57 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $358.23 | 2021-2024 | Nexletol |
| Pfizer INC. | $330.59 | 2021-2025 | |
| Astellas Pharma US INC | $279.99 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $222.96 | 2022-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $176.51 | 2021-2024 | Belsomra, Verquvo, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $175.12 | 2022-2025 | Xarelto, Spravato |
| Exact Sciences Corporation | $172.83 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $136.64 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $125.57 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $123.36 | 2022 | |
| Phathom Pharmaceuticals, INC. | $112.80 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $106.23 | 2024-2025 | Auvelity |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.